reviewed april 2026|next review october 2026|88 physicians psi has verified|27 published studies
Orexin-A (Hypocretin-1)
Orexin-A (hypocretin-1) is a naturally occurring (the body's own) neuropeptide that regulates wakefulness, appetite, and reward, with loss of orexin-producing neurons as the established cause of narcolepsy and two FDA-approved orexin receptor antagonists (suvorexant/Belsomra, lemborexant/Dayvigo) used for insomnia.
Evidence landscape: 27 published studies
27 published items indexed under this slug. The broader orexin/hypocretin literature exceeds 8,000 studies.
- 3 Human
- 23 Animal
- 1 Reviews
Orexin-A itself is not a drug. Two FDA-approved orexin receptor antagonists (suvorexant/Belsomra, lemborexant/Dayvigo) block orexin signaling for insomnia treatment. Orexin receptor agonists for narcolepsy are in clinical development.
Orexin-A is a naturally occurring (the body's own) neuropeptide, not a pharmaceutical product. The FDA-approved antagonists are available by prescription. Agonist development is in clinical trials only.
Master regulator of wakefulness. Loss of orexin-producing neurons causes narcolepsy type 1. The therapeutic validation came from blocking the pathway (insomnia drugs), not supplementing it.
PSI Assessment
Two independent research groups discovered the same neuropeptide simultaneously in 1998, one naming it orexin (from the Greek for appetite) and the other hypocretin (from its hypothalamic origin). The convergence of these discoveries revealed a master regulator of wakefulness, appetite, and reward signaling. Within two years, the loss of orexin-producing neurons was identified as the cause of narcolepsy. The therapeutic validation came from the opposite direction: blocking orexin receptors with suvorexant (Belsomra) and lemborexant (Dayvigo) is FDA-approved for insomnia. An orexin receptor agonist (TAK-994/danavorexton) for narcolepsy reached Phase II before a safety hold.
Discovered simultaneously by two groups in 1998. Loss of orexin neurons causes narcolepsy. Two FDA-approved orexin antagonists for insomnia. Agonist development ongoing.
The mechanism is hypothalamic arousal regulation through OX1R and OX2R (orexin receptor 1 and 2). Orexin-producing neurons in the lateral hypothalamus project widely throughout the brain, promoting wakefulness, suppressing REM sleep, stimulating appetite, and modulating reward circuits. Loss of these neurons (approximately 70,000 in humans) causes narcolepsy type 1 with cataplexy. Blocking orexin receptors with dual orexin receptor antagonists (DORAs) promotes sleep without the dependency risk of older sedatives.
What the evidence supports
Orexin-A is established as a master regulator of wakefulness, with loss of orexin neurons as the established cause of narcolepsy type 1. Two FDA-approved orexin receptor antagonists (suvorexant, lemborexant) validate the pathway for insomnia treatment. The simultaneous 1998 discovery by two independent groups and rapid identification of the narcolepsy link is one of the most elegant examples of translational neuroscience.
What is not yet established
Whether orexin receptor agonists can safely treat narcolepsy (TAK-994 was placed on safety hold). Optimal therapeutic use of exogenous orexin-A versus receptor-targeted drugs. Whether orexin modulation has therapeutic potential for appetite disorders or addiction. Long-term effects of chronic orexin receptor antagonism.
Research Evidence
The findings below cover what the orexin discovery established, how the pathway was validated therapeutically, and where agonist development currently stands.
Evidence by condition
Evidence dimensions across orexin-A's investigated applications. Insomnia treatment via receptor antagonism is FDA-approved. Narcolepsy agonist therapy is in clinical development. Appetite and wakefulness research is from animal studies.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Narcolepsy | ||||
| Insomnia/DORA | ||||
| Appetite/Reward | ||||
| Wakefulness Research |
Two independent groups (de Lecea et al. and Sakurai et al.) simultaneously discovered orexin/hypocretin in 1998. Within two years, Thannickal et al. identified loss of orexin neurons as the cause of narcolepsy type 1.
The simultaneous discovery and rapid disease-mechanism identification is one of the most elegant examples of translational neuroscience.
Two FDA-approved dual orexin receptor antagonists (suvorexant/Belsomra, lemborexant/Dayvigo) validate the pathway for insomnia treatment. These drugs promote sleep by blocking orexin's wake-promoting signal.
The therapeutic validation came from blocking orexin, not supplementing it. These drugs do not carry the dependency risk of benzodiazepines.
Orexin receptor agonist development for narcolepsy (TAK-994/danavorexton) reached Phase II before a safety hold. Agonist development continues through alternative programs.
The safety hold on TAK-994 illustrates the difficulty of replacing a naturally occurring (the body's own) neuropeptide pharmacologically. The agonist approach remains unvalidated.
3 Human|23 Animal|1 Reviews
View all 27 indexed studiesHow Orexin-A (Hypocretin-1) Works
Orexin-A is a 33-amino-acid naturally occurring (the body's own) neuropeptide produced by approximately 70,000 neurons in the lateral hypothalamus.
Orexin-A is the brain's primary 'stay awake' signal. A small group of neurons in the hypothalamus produces orexin and broadcasts it throughout the brain, maintaining alertness. In narcolepsy, the immune system destroys these neurons, causing sudden uncontrollable sleep episodes. Insomnia drugs like Belsomra work by blocking orexin's wake signal.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Orexin-A is a 33-amino acid peptide that binds to OX1R and OX2R G-protein-coupled receptors. Orexin neurons in the lateral hypothalamus project widely throughout the brain, activating monoaminergic wake-promoting centers. Loss of orexin neurons causes narcolepsy type 1 with cataplexy.
What is Orexin-A (Hypocretin-1) being studied for?
Researchers are studying Orexin-A (Hypocretin-1) across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Orexin-A (Hypocretin-1) overall. This means a compound can have human studies for one condition but only animal data for another.
Narcolepsy
·Human TrialsLoss of orexin-producing neurons is the established cause of narcolepsy type 1. CSF orexin-A levels below 110 pg/mL are diagnostic. Orexin receptor agonist development for narcolepsy treatment is ongoing.
Limitations: No orexin replacement therapy is yet FDA-approved. TAK-994 (agonist) was placed on safety hold. The agonist approach remains unvalidated.
Insomnia/DORA
·FDA ApprovedFDA-approved orexin receptor antagonists (suvorexant, lemborexant) treat insomnia by blocking orexin's wake-promoting signal. These represent a new drug class without the dependency risk of benzodiazepines.
Limitations: Side effects include next-day drowsiness and rare sleep paralysis. Not all insomnia responds to orexin antagonism.
Appetite/Reward
·Animal StudiesOrexin-A stimulates appetite and links wakefulness to feeding behavior. Narcolepsy patients have higher rates of obesity despite eating similar amounts.
Limitations: Metabolic applications of orexin modulation are investigational. Appetite effects are secondary to the wakefulness research.
Wakefulness Research
·Animal StudiesOrexin-A is the primary naturally occurring wake-promoting signal. Research into orexin agonists for disorders of excessive daytime sleepiness beyond narcolepsy is ongoing.
Limitations: Exogenous orexin-A administration for wakefulness enhancement is not established. Safety of chronic orexin receptor agonism is unknown.
Safety and Regulatory Status
FDA Status: Orexin-A itself is not a drug product. Orexin receptor antagonists (suvorexant/Belsomra, lemborexant/Dayvigo) are FDA-approved for insomnia. Orexin agonists are in clinical development.
Availability: Naturally occurring (the body's own) neuropeptide. Not available as a pharmaceutical product. The FDA-approved antagonists are prescription medications.
Class context: The FDA-approved antagonists have well-characterized safety profiles. Main concerns are next-day drowsiness and rare sleep-related behaviors. The agonist safety profile is not yet established (TAK-994 placed on safety hold).
Orexin-A is a naturally occurring (the body's own) neuropeptide. The safety discussion centers on drugs that modulate the orexin pathway. FDA-approved antagonists (Belsomra, Dayvigo) have favorable safety profiles with next-day drowsiness as the main concern. Orexin agonist safety is not yet established.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a Orexin-A (Hypocretin-1) discussion.
Comparison and Related Research
Orexin-A is most often compared with other sleep-regulating neuropeptides and wakefulness-promoting agents.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.The discovery paper for the orexin system. This study identified two novel neuropeptides, orexin-A and orexin-B, produced by a small cluster of neurons in the lateral hypothalamus, along with two G protein-coupled receptors (OX1R and OX2R). The orexins were initially characterized for their role in stimulating feeding behavior, but subsequent research revealed their far more fundamental role in regulating wakefulness and arousal.Sakurai T et al., 1998 in Cell. View on PubMed
- 2.Independent co-discovery of the same neuropeptide system, named hypocretins by this research group. Published shortly before the Sakurai paper, this study identified two hypothalamus-specific peptides with neuroexcitatory properties. The parallel discovery by two independent groups, using different approaches, underscored the biological importance of this signaling system.de Lecea L et al., 1998 in Proc Natl Acad Sci U S A. View on PubMed
- 3.Post-mortem study that provided the critical link between orexin/hypocretin deficiency and human narcolepsy. Examination of brain tissue from narcolepsy patients revealed an 85-95% reduction in the number of orexin-producing neurons compared to controls. This finding transformed the understanding of narcolepsy from a poorly understood sleep disorder to a neurodegenerative condition targeting a specific neuronal population.Thannickal TC et al., 2000 in Neuron. View on PubMed
- 4.Review by a leading narcolepsy researcher synthesizing the first several years of orexin research into a coherent model of sleep-wake regulation. The paper describes how orexin neurons function as a stabilizing switch for the sleep-wake cycle, and how their loss explains the core symptoms of narcolepsy: excessive daytime sleepiness, cataplexy, and disrupted nighttime sleep. This framework laid the foundation for orexin receptor-targeted therapeutics.Mignot E, 2002 in Nat Neurosci. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.